Australian patent law

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
NDA, Woman, Prejudice, Urinary tract infection, Food, Probenecid, Therapy, Investment, South Korean Patent Act, Patient, ITRM, Research, Infection, FDA, G&A, New Drug Application, National Renewable Energy Laboratory, CRL, Symantec Endpoint Protection, R, Patent, Australian patent law, Pharmaceutical industry

DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2023.
  • Iterum expects to report top-line data early in the first quarter of 2024 and, subject to its analysis of the data, to resubmit its New Drug Application (NDA) in the second quarter of 2024.
  • Research and development (R&D) expenses for the third quarter 2023 were $14.9 million, compared to $4.4 million for the same period in 2022.
  • Iterum will host a conference call today, Tuesday, November 14, 2023 at 8:30 a.m. Eastern Time.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

ShardSecure® Announces Allowance of Pivotal US Patent Application

Retrieved on: 
Tuesday, June 20, 2023
Patent, Australian patent law, Patent application, TAG, Privacy, Organization, Cryptocurrency, Medical device

NEW YORK, June 20, 2023 /PRNewswire/ -- ShardSecure, a leading provider of cloud data security and resilience software, is pleased to announce its receipt of a Notice of Allowance related to our pivotal US patent application covering the current ShardSecure platform.

Key Points: 
  • NEW YORK, June 20, 2023 /PRNewswire/ -- ShardSecure, a leading provider of cloud data security and resilience software, is pleased to announce its receipt of a Notice of Allowance related to our pivotal US patent application covering the current ShardSecure platform.
  • This US Patent is part of the initial ShardSecure patent family, which comprises an Australian Patent, Canadian Patent Application, and EP Patent Application.
  • In addition to this initial patent family, ShardSecure remains focused on protecting its innovation through the filing of at least two new patent families leveraging additional technical improvement of the ShardSecure platform.
  • We anticipate that this US patent will strengthen customer trust in the ShardSecure platform and its specific benefits for data protection."

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Wednesday, January 11, 2023
RCE, Viral, Inhalation, Patent, Virus, Administration, HIV, Severe acute respiratory syndrome coronavirus 2, FSE, Recce, Treatment, ASX, Hepatitis, IP, Australian patent law, Pharmaceutical industry, Vaccine

SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”

Key Points: 
  • SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”
    “Receiving notice that this Australian patent application will proceed to grant is another milestone in the Company’s global IP strategy, and we are thrilled by the further validation of the potential importance of our infectious disease compounds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Australian Patent is expected to grant claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably:
    Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, (human immunodeficiency virus) HIV, hepatitis, Ross River and herpes viruses
    Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
    This is the final patent of family three (expiry: November 2037), following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe, Hong Kong, and the United States.

Asep Inc. is Granted Patent Approval for its Sepsis Diagnostic Technology in 13 European Countries and Australia

Retrieved on: 
Monday, November 7, 2022
High-dependency unit, Company, Mortality, European Patent Convention, Skin, Multimedia, CSE, Patent, Death, Overalls, Risk, Australian patent law, FDA, Disease, Sepsis, ASEP, TM, Throat, UBC, COVID-19, Trial of the century, Intention, Review, Health, CEO, Prognosis, US Foods, Physician, Lung, View, Forward-looking statement, Technology, News, Diagnosis, Survival, Patient, Sinusitis, Solution, Television, Pharmaceutical industry, Medical device, Vaccine, Medicine, BC

VANCOUVER, BC, Nov. 7, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the"Company") (CSE: ASEP) (OTCQB: SEPSF)is very pleased to announce that the Company's sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in 13 European countries as well as in Australia.

Key Points: 
  • VANCOUVER, BC, Nov. 7, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the"Company") (CSE: ASEP) (OTCQB: SEPSF)is very pleased to announce that the Company's sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in 13 European countries as well as in Australia.
  • The Company also was awarded a patent in Australia (Australian Patent No.
  • The technology, named SepsetER, is a blood-based gene expression assay developed under the direction of leading UBC microbiologist and Asep Inc.'s Founding Director and current CEO, Dr. Robert E. W. Hancock.
  • The patent licensing arrangement gives Asep Inc.'s subsidiary, Sepset Biosciences Inc., exclusive worldwide rights to develop the sepsis severity signature into a diagnostic test and bring the test to market.

Proactive news headlines including West Wits Mining, Archer Materials, Celsius Resources and Creso Pharma

Retrieved on: 
Monday, May 23, 2022
Well, Spend, Lithium, Copper, IBG, CLA, White Rock, BNL, CRR, OTCQB, YRL, Voyager, Gibsons, Nickel, OTCQX, EPM, JV, ASX, WBP, Sempra Metals Ltd v IRC, Silver, DAF, Coal Creek, GLOBE, Proactivity, APC, Aviation, Australian patent law, Program, IMU, LNS, WRM, MCB, CPH, Patent, Lead, Gold, OTC, Amax Potash Ltd v Saskatchewan, EMS, LIBS, Heads of Agreement, Memorandum of understanding, Technology, Cooper Basin, BLU, Renewable energy, Oil, Rare-earth element, Financial services, Mining, NSW, HOA, The Long canyon (quarry)

Click here

Key Points: 
  • Click here
    Imugene Ltd (ASX:IMU, OTC:IUGNF)s chairman says the company is as strong as it has ever been in its history despite challenges in the global biotech market.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]